Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Lip Neoplasms

• Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer
• Addition of Aspirin to Standard of Care in Oral Cancer
• A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During Surgery
• Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Stage III-IVB Head and Neck Cancer
• BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
• Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers
• 68Ga-FAPI-04 PET/CT for the Detection of Oral Carcinoma
• Topical Aldara (Imiquimod) for Oral Cancer
• Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
• Testing the Addition of an Anti-cancer Drug, BAY1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer
• Sodium Thiosulfate for the Prevention of Ototoxicity in Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck Undergoing Chemoradiation With Cisplatin
• Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin
• Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
• Fluorescence-guided Surgery Using cRGD-ZW800-1 in Oral Cancer
• Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
• Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT
• Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors
• Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors
• IACS-010759 in Advanced Cancers
• Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer
• Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies
• Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma
• Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
• Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
• Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation
• Lenvatinib and Capecitabine in Patients With Advanced Malignancies
• Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies
• Multimodal Imaging for Surveillance in Patients With Oral Potentially Malignant Disorders
• Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
• Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer.
• Erlotinib Prevention of Oral Cancer (EPOC)
• Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia
• ONYX-015 With Cisplatin and Fluorouracil in Treating Patients With Advanced Head and Neck Cancer